Search results
Showing 1621 to 1635 of 9046 results
Evidence-based recommendations on tisotumab vedotin (Tivdak) for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment in adults.
Show all sections
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults.
Evidence-based recommendations on lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment in adults.
Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma in adults.
Show all sections
Sotatercept for treating pulmonary arterial hypertension (TA1161)
Evidence-based recommendations on sotatercept (Winrevair) for pulmonary arterial hypertension in adults.
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over (TA1031)
Evidence-based recommendations on vamorolone (Agamree) for treating Duchenne muscular dystrophy in people 4 years and over.
Show all sections
Evidence-based recommendations on osimertinib (Tagrisso) for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy in adults.
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment in adults.
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over (TA1157)
Evidence-based recommendations on givinostat (Duvyzat) for treating Duchenne muscular dystrophy in people 6 years and over.
NICE is unable to make a recommendation on nogapendekin alfa inbakicept (Anktiva) with Bacillus Calmette-Guérin (BCG) for non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumours, that is unresponsive to BCG in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1163
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.
Nusinersen and risdiplam for treating spinal muscular atrophy (TA1162)
Evidence-based recommendations on nusinersen (Spinraza) and risdiplam (Evrysdi) for treating spinal muscular atrophy.
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)
Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors.
NICE is unable to make a recommendation on baloxavir marboxil (Xofluza) for treating acute uncomplicated influenza in people aged 12 and over. This is because Roche did not provide an evidence submission.
Show all sections
Sections for TA732
Evidence-based recommendations on cemiplimab (Libtayo) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer in adults.